Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Autologous genetically modified AFPᶜ³³²T cells
ADP-A2AFP · 1 trial · 2 indications
Number of participants experiencing at least one dose-limiting toxicity (DLT) following administration of autologous genetically modified AFPᶜ³³²T cells, assessed during the protocol-defined DLT evaluation period.
Number of participants experiencing at least one treatment-emergent adverse event (TEAE) following administration of lymphodepleting chemotherapy and autologous genetically modified AFPᶜ³³²T cells.
Number of participants experiencing at least one serious adverse event (SAE) following administration of lymphodepleting chemotherapy and autologous genetically modified AFPᶜ³³²T cells
| Arm | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | GENETIC | Infusion of autologous genetically modified AFPᶜ³³²T cells |
Key Inclusion Criteria: 1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations. 2. Histologically confirmed HCC, not amenable to transplant, resection. Subject...
ADP-A2AFP is an investigational autologous genetically modified T-cell therapy developed by Adaptimmune Therapeutics for hepatocellular cancer and other AFP-expressing tumors. It is a gene therapy approach in which a patient's own T cells are engineered and then returned to the patient. It has been studied in a single Phase 1 trial.
ADP-A2AFP has been studied for hepatocellular cancer and AFP-expressing tumors. The Phase 1 trial enrolled adults 18 years and older with advanced HCC. It is an investigational therapy and is not an approved treatment for hepatocellular cancer or any other indication.
ADP-A2AFP is developed by Adaptimmune Therapeutics PLC, which trades under the ticker ADAPY. The company sponsored the Phase 1 study of the therapy in advanced hepatocellular cancer and AFP-expressing tumors across the United States, France, Spain, and the United Kingdom.
ADP-A2AFP is in Phase 1 development. Its single clinical trial, NCT03132792, is a completed Phase 1 study that enrolled 39 patients. ADP-A2AFP is investigational and has not been approved by the FDA for any indication.
ADP-A2AFP has been evaluated in one clinical trial, NCT03132792, titled AFPᶜ³³²T in Advanced HCC. The completed Phase 1 study enrolled 39 patients with hepatocellular cancer or AFP-expressing tumors in the United States, France, Spain, and the United Kingdom. It was an uncontrolled study open to all sexes.
Yes. ADP-A2AFP is also known as autologous genetically modified AFPᶜ³³²T cells. Both names refer to the same Adaptimmune Therapeutics T-cell therapy studied in the Phase 1 trial NCT03132792 in advanced hepatocellular cancer and AFP-expressing tumors.